tetano
Editor, Senior Moderator
Vaccine
. 2024 Aug 23;42(23):126221.
doi: 10.1016/j.vaccine.2024.126221. Online ahead of print. Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study
Kohei Unagami[SUP] 1 [/SUP], Mikiko Yoshikawa[SUP] 2 [/SUP], Hiroto Egawa[SUP] 3 [/SUP], Satoko Ohfuji[SUP] 4 [/SUP], Yoichiro Natori[SUP] 5 [/SUP], Rikako Oki[SUP] 6 [/SUP], Tomomi Mori[SUP] 7 [/SUP], Hidetoshi Hattori[SUP] 8 [/SUP], Ayumi Ishiwatari[SUP] 9 [/SUP], Taichi Kanzawa[SUP] 10 [/SUP], Tomokazu Shimizu[SUP] 11 [/SUP], Kazuya Omoto[SUP] 10 [/SUP], Masashi Inui[SUP] 10 [/SUP], Yuuki Masano[SUP] 12 [/SUP], Takashi Ito[SUP] 12 [/SUP], Daisuke Nakajima[SUP] 13 [/SUP], Tetsuya Babazono[SUP] 7 [/SUP], Toshio Takagi[SUP] 14 [/SUP], Shinichi Nunoda[SUP] 15 [/SUP], Yoshito Tomimaru[SUP] 16 [/SUP], Ryoichi Imamura[SUP] 17 [/SUP], Shigeru Miyagawa[SUP] 18 [/SUP], Koichi Toda[SUP] 18 [/SUP], Etsuro Hatano[SUP] 12 [/SUP], Hiroshi Date[SUP] 13 [/SUP], Miyaji Kyakuno[SUP] 19 [/SUP], Shiro Takahara[SUP] 20 [/SUP], Kenji Yuzawa[SUP] 21 [/SUP], Naoki Tanimine[SUP] 22 [/SUP], Hideki Ohdan[SUP] 22 [/SUP], Hideki Ishida[SUP] 23 [/SUP], Yoshio Hirota[SUP] 24 [/SUP]; Japan Solid Organ Transplantation COVID-19 Countermeasure Group
Affiliations
Poor post-vaccination production of antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a concern among solid organ transplant (SOT) recipients. Furthermore, the timing and kinetics of antibody titers after the second vaccine dose are unknown. We conducted a multicenter prospective observational study that included 614 SOT recipients: 460 kidney, 53 heart, 50 liver, 20 lung, and 31 simultaneous pancreas-kidney (SPK). The participants received two doses of the mRNA vaccine (Pfizer BNT162b2 or Moderna mRNA-1273), as indicated. Serum samples were collected before the first and second vaccinations and at 1, 3, and 6 months after the second vaccine dose, which were then assessed for SARS-CoV-2 antibodies. The overall seropositivity rate was 43% at 1 month after administration of the second vaccine dose; it gradually increased to 68% at 3 months after second dose administration and to 70% at 6 months. In addition, recipient of kidney, lung or SPK transplants had lower antibody titers at the 3- and 6-month time points than did the other recipients. SOT recipients acquired SARS-CoV-2 S-IgG antibodies slowly, and the peak titer differed significantly from that of the general population.
Keywords: Immunosuppressive therapy; Post-vaccination antibody; Prospective cohort study; SARS-CoV-2 vaccine; Solid organ transplantation.
. 2024 Aug 23;42(23):126221.
doi: 10.1016/j.vaccine.2024.126221. Online ahead of print. Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study
Kohei Unagami[SUP] 1 [/SUP], Mikiko Yoshikawa[SUP] 2 [/SUP], Hiroto Egawa[SUP] 3 [/SUP], Satoko Ohfuji[SUP] 4 [/SUP], Yoichiro Natori[SUP] 5 [/SUP], Rikako Oki[SUP] 6 [/SUP], Tomomi Mori[SUP] 7 [/SUP], Hidetoshi Hattori[SUP] 8 [/SUP], Ayumi Ishiwatari[SUP] 9 [/SUP], Taichi Kanzawa[SUP] 10 [/SUP], Tomokazu Shimizu[SUP] 11 [/SUP], Kazuya Omoto[SUP] 10 [/SUP], Masashi Inui[SUP] 10 [/SUP], Yuuki Masano[SUP] 12 [/SUP], Takashi Ito[SUP] 12 [/SUP], Daisuke Nakajima[SUP] 13 [/SUP], Tetsuya Babazono[SUP] 7 [/SUP], Toshio Takagi[SUP] 14 [/SUP], Shinichi Nunoda[SUP] 15 [/SUP], Yoshito Tomimaru[SUP] 16 [/SUP], Ryoichi Imamura[SUP] 17 [/SUP], Shigeru Miyagawa[SUP] 18 [/SUP], Koichi Toda[SUP] 18 [/SUP], Etsuro Hatano[SUP] 12 [/SUP], Hiroshi Date[SUP] 13 [/SUP], Miyaji Kyakuno[SUP] 19 [/SUP], Shiro Takahara[SUP] 20 [/SUP], Kenji Yuzawa[SUP] 21 [/SUP], Naoki Tanimine[SUP] 22 [/SUP], Hideki Ohdan[SUP] 22 [/SUP], Hideki Ishida[SUP] 23 [/SUP], Yoshio Hirota[SUP] 24 [/SUP]; Japan Solid Organ Transplantation COVID-19 Countermeasure Group
Affiliations
- PMID: 39180977
- DOI: 10.1016/j.vaccine.2024.126221
Poor post-vaccination production of antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a concern among solid organ transplant (SOT) recipients. Furthermore, the timing and kinetics of antibody titers after the second vaccine dose are unknown. We conducted a multicenter prospective observational study that included 614 SOT recipients: 460 kidney, 53 heart, 50 liver, 20 lung, and 31 simultaneous pancreas-kidney (SPK). The participants received two doses of the mRNA vaccine (Pfizer BNT162b2 or Moderna mRNA-1273), as indicated. Serum samples were collected before the first and second vaccinations and at 1, 3, and 6 months after the second vaccine dose, which were then assessed for SARS-CoV-2 antibodies. The overall seropositivity rate was 43% at 1 month after administration of the second vaccine dose; it gradually increased to 68% at 3 months after second dose administration and to 70% at 6 months. In addition, recipient of kidney, lung or SPK transplants had lower antibody titers at the 3- and 6-month time points than did the other recipients. SOT recipients acquired SARS-CoV-2 S-IgG antibodies slowly, and the peak titer differed significantly from that of the general population.
Keywords: Immunosuppressive therapy; Post-vaccination antibody; Prospective cohort study; SARS-CoV-2 vaccine; Solid organ transplantation.